Baldwin Wealth Partners LLC MA Lowers Stake in Novartis AG (NYSE:NVS)

Baldwin Wealth Partners LLC MA trimmed its holdings in Novartis AG (NYSE:NVS) by 11.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 48,278 shares of the company’s stock after selling 6,527 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Novartis were worth $4,698,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in NVS. Mirae Asset Global Investments Co. Ltd. lifted its position in Novartis by 115.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock worth $26,797,000 after acquiring an additional 124,111 shares during the period. CWA Asset Management Group LLC lifted its holdings in shares of Novartis by 20.1% during the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock worth $3,001,000 after purchasing an additional 5,164 shares during the period. Quantbot Technologies LP lifted its holdings in shares of Novartis by 135.5% during the third quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after purchasing an additional 22,998 shares during the period. Charles Schwab Investment Management Inc. grew its position in Novartis by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 157,256 shares of the company’s stock valued at $18,088,000 after buying an additional 18,990 shares during the last quarter. Finally, Natixis Advisors LLC increased its stake in Novartis by 2.9% in the 3rd quarter. Natixis Advisors LLC now owns 938,844 shares of the company’s stock valued at $107,986,000 after buying an additional 26,317 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Performance

NYSE NVS opened at $102.29 on Monday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92. The firm has a market capitalization of $209.08 billion, a P/E ratio of 11.89, a P/E/G ratio of 1.42 and a beta of 0.57. The business’s 50-day simple moving average is $100.09 and its 200-day simple moving average is $108.69.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The firm had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the prior year, the firm earned $1.74 EPS. Equities analysts predict that Novartis AG will post 7.62 EPS for the current year.

Analyst Ratings Changes

NVS has been the topic of several analyst reports. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Finally, BMO Capital Markets raised their price target on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Two analysts have rated the stock with a sell rating and six have given a hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.